Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.61 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | ANPEP | P15144 | 1/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.58 |
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.57 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.57 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3181613 | 1.00 | DPP8 (0.61) | DPP8DPP7HTTANPEPFOLH1 | |
| SCHEMBL2033858 | 1.00 | DPP8 (0.61) | DPP8DPP7HTTANPEPFOLH1 | |
| SCHEMBL2228405 | 0.99 | DPP8 (0.60) | DPP8DPP7HTTANPEPFOLH1 | |
| SCHEMBL6375258 | 0.96 | HTT (0.62) | DPP8DPP7HTTANPEPFOLH1 | |
| Hydrochloric Acid SCHEMBL6374328 | 0.95 | HTT (0.60) | DPP8DPP7HTTANPEPFOLH1 | |
| SCHEMBL1586919 | 0.90 | DPP8 (0.61) | DPP8DPP7HTTANPEPFOLH1 | |
| SCHEMBL1586916 | 0.90 | DPP8 (0.61) | DPP8DPP7HTTANPEPFOLH1 | |
| SCHEMBL9772232 | 0.88 | HTT (0.63) | DPP8DPP7HTTANPEPFOLH1 | |
| SCHEMBL9772226 | 0.88 | HTT (0.63) | DPP8DPP7HTTANPEPFOLH1 | |
| SCHEMBL27784040 | 0.87 | DPP8 (0.59) | DPP8DPP7HTTANPEPFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415789-B2 | Macrocycles comprising a 4-amido-2,4-pentadienoate moiety for the treatment of hypoxic cancers | AARHUS UNIVERSITET (DK) | 2025-09-16 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20230020952-A1 | MACROCYCLES COMPRISING A 4-AMIDO-2,4-PENTADIENOATE MOIETY FOR THE TREATMENT OF HYPOXIC CANCERS | AARHUS UNIVERSITET (DK) | 2023-01-19 | — | — | US | disclosed |
| EP-4069217-A1 | MACROCYCLES COMPRISING A 4-AMIDO-2,4-PENTADIENOATE MOIETY FOR THE TREATMENT OF HYPOXIC CANCERS | Aarhus Universitet (DK) | 2022-10-12 | — | — | EP | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-10633630-B2 | Acceleration of Mycobacterium growth | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2020-04-28 | — | — | US | disclosed |
| EP-3158053-B1 | ACCELERATION OF MYCOBACTERIUM GROWTH | ST GEORGES HOSPITAL MEDICAL SCHOOL (GB) | 2019-03-13 | — | — | EP | disclosed |
| EP-2061886-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | The University of British Columbia (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008022444-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-02-28 | — | — | WO | disclosed |
| EP-0687251-B1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI SYNTHELABO (FR) | 2002-02-27 | — | — | EP | disclosed |
| US-6153608-A | Isoquinoline derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2000-11-28 | — | — | US | disclosed |
| EP-0885888-A1 | ISOQUINOLINE DERIVATIVES AND DRUGS | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5773612-A | VASOPRESSIN OR OXYTOCIN RECEPTORS | SANOFI (FR) | 1998-06-30 | — | — | US | disclosed |
| US-5594023-A | 1,3-dihydroindol-2-one derivatives substituted in the 3-position by a nitrogen-containing group, their preparation and the pharmaceutical compositions in which they are present | SANOFI (FR) | 1997-01-14 | — | — | US | disclosed |
| EP-0687251-A1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI (FR) | 1995-12-20 | — | — | EP | disclosed |
| WO-1995018105-A1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI (FR) | 1995-07-06 | — | — | WO | disclosed |
| US-4596819-A | Antidepressive agents | WARNER-LAMBERT COMPANY (US) | 1986-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020952-A1 | MACROCYCLES COMPRISING A 4-AMIDO-2,4-PENTADIENOATE MOIETY FOR THE TREATMENT OF HYPOXIC CANCERS | DLD, HIF1A, DPYD | DPP8 1745/4885DPP7 1116/4885HTT 3052/4885 |
| US-12415789-B2 | Macrocycles comprising a 4-amido-2,4-pentadienoate moiety for the treatment of hypoxic cancers | DLD, HIF1A, DPYD | DPP8 1745/4885DPP7 1116/4885HTT 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.